Curis, Inc. (CRIS) Scientists Present Strategic Compound Design at the 235th American Chemical Society (ACS) National Meeting
Curis, Inc, a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to create new medicines, announced that its scientists presented a poster entitled “Design and synthesis of quinazoline derivatives as novel, potent multi-acting HDAC and receptor tyrosine kinase inhibitors for the treatment of cancer,” at the 235th ACS National Meeting. The ACS National Meeting is being held from April 6th through the 10th. The compound design and research underlying the development of proprietary drug compounds, belonging to a class of chemical structures called quinazonlines, was described at the presentation. The compounds were designed to…